Begins Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)

Research analysts at began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVBGet Rating) in a research note issued on Saturday. The firm set a “sell” rating on the stock.

Navidea Biopharmaceuticals Price Performance

Shares of Navidea Biopharmaceuticals stock opened at $0.23 on Friday. Navidea Biopharmaceuticals has a 12-month low of $0.21 and a 12-month high of $1.55. The business’s 50 day moving average is $0.27 and its 200-day moving average is $0.58. The stock has a market cap of $7.48 million, a P/E ratio of -0.58 and a beta of 1.36.

Navidea Biopharmaceuticals (NYSE:NAVBGet Rating) last posted its quarterly earnings results on Monday, August 15th. The company reported ($0.10) earnings per share for the quarter. The company had revenue of $0.06 million during the quarter.

Navidea Biopharmaceuticals Company Profile

(Get Rating)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.

Recommended Stories

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.